Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.70 |
| ▸ | GAA | P10253 | 2/20 | 0.70 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15023825 | 0.87 | SMN1; SMN2 (0.57) | MAPTGAASMN1; SMN2TAAR1ALDH1A1 | |
| SCHEMBL15033614 | 0.87 | ALDH1A1 (0.58) | MAPTGAAALOX12SMN1; SMN2TAAR1 | |
| SCHEMBL15023249 | 0.84 | RAB9A (0.58) | MAPTGAASMN1; SMN2TAAR1ALDH1A1 | |
| SCHEMBL15033619 | 0.84 | MEN1 (0.55) | MAPTGAAALOX12SMN1; SMN2TAAR1 | |
| SCHEMBL15023200 | 0.84 | GAA (0.57) | MAPTGAAALOX12SMN1; SMN2ALDH1A1 | |
| SCHEMBL15023823 | 0.84 | GAA (0.57) | MAPTGAAALOX12SMN1; SMN2ALDH1A1 | |
| SCHEMBL15033637 | 0.84 | GAA (0.59) | MAPTGAAALOX12SMN1; SMN2ALDH1A1 | |
| SCHEMBL15023041 | 0.82 | GAA (0.57) | MAPTGAAALOX12SMN1; SMN2ALDH1A1 | |
| SCHEMBL15023829 | 0.79 | LMNA (0.74) | MAPTGAAALOX12SMN1; SMN2ALDH1A1 | |
| SCHEMBL15022897 | 0.79 | GAA (0.54) | MAPTGAAALOX12SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158112-A1 | COMPOSITIONS AND METHODS FOR INHIBITING BETA AMYLOID SECRETION | CASE WESTERN RESERVE UNIVERSITY | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158112-A1 | COMPOSITIONS AND METHODS FOR INHIBITING BETA AMYLOID SECRETION | IAPP, APP, BACE1 | MAPT 38/4885GAA 238/4885ALOX12 1590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.